耐药结核病经济负担研究进展  

Progress on economic burden of patients with drug-resistant tuberculosis

作　　者：王泊宁 李涛[1] 陈伟[1] Wang Boning;Li Tao;Chen Wei(National Center for Tuberculosis Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing 102206,China)

机构地区：[1]中国疾病预防控制中心结核病预防控制中心,北京102206

出　　处：《中国防痨杂志》2023年第6期607-612,共6页Chinese Journal of Antituberculosis

基　　金：“十三五”国家科技重大专项(2017ZX10201302-007)。

摘　　要：尽管全球结核病疫情呈现下降趋势,耐药结核病的经济负担却日益加重。究其原因,耐药结核病的治疗药物昂贵,病程迁延不愈,治疗不良反应严重。作者对耐药结核病经济负担进行综述,揭示目前耐药结核病经济负担的研究现状及其影响因素,以期为后续研究和医保政策制订提供参考。While the global tuberculosis epidemic has shown a decline trend in recent years,the economic burden induced by drug-resistant tuberculosis has increased.The reason is that the treatment of drug-resistant tuberculosis is expensive,the course of the disease is prolonged,and the side effects of treatment are serious.The authors reviewed the economic burden of drug-resistant tuberculosis and revealed the current research status of the economic burden of drug-resistant tuberculosis and its influencing factors to provide a reference for subsequent researches and medical insurance policy formulation.

关 键 词：结核 抗药性 经济学 医学 患病代价 综述文献(主题) 

分 类 号：R521[医药卫生—内科学]